Last updated: September 4, 2026
Ethrane, the former Abbott brand for enflurane, is a legacy volatile inhalational anesthetic with no meaningful current commercial market in the United States. Its patent and regulatory exclusivity periods expired decades ago. Commercial demand shifted to newer anesthetics, especially sevoflurane, desflurane, isoflurane, and intravenous propofol. Ethrane has no identifiable growth trajectory, active branded revenue base, or material patent-driven barrier to substitution.
What is Ethrane and how was it used?
Ethrane is the brand name for enflurane, a halogenated ether used for the induction and maintenance of general anesthesia. It was administered through an anesthesia vaporizer and typically used with oxygen or nitrous oxide.
Enflurane entered clinical use during the 1970s. Its pharmacologic profile included:
| Attribute |
Ethrane / enflurane |
| Active ingredient |
Enflurane |
| Drug class |
Volatile inhalational general anesthetic |
| Dosage form |
Inhalational liquid for vaporization |
| Original commercial company |
Abbott Laboratories |
| Primary use |
Induction and maintenance of general anesthesia |
| U.S. commercial status |
Legacy/discontinued product |
| Current patent value |
Negligible |
| Principal substitutes |
Sevoflurane, desflurane, isoflurane, propofol |
| Biosimilar relevance |
None |
Enflurane had a relatively high blood-gas solubility compared with sevoflurane and desflurane, which contributed to slower changes in anesthetic depth and recovery. It also had clinically important adverse-effect considerations, including dose-related respiratory and cardiovascular depression and the potential for fluoride metabolite formation. The product label warned about seizure-like activity and increased risk in patients with certain neurologic conditions.[1]
When did Ethrane lose exclusivity?
Ethrane lost meaningful market exclusivity long before the modern generic-drug framework became commercially important.
The original composition-of-matter and product patents covering enflurane were not active during the current period. No commercially significant patent barrier remains around the active ingredient. Any historical U.S. patent protection would have expired by the late twentieth century, well before the growth of modern inhaled-anesthetic competitors.
| Exclusivity category |
Ethrane status |
| Composition-of-matter protection |
Expired decades ago |
| Original product patents |
Expired |
| Regulatory exclusivity |
Expired |
| Pediatric exclusivity |
Not commercially relevant |
| Orphan-drug exclusivity |
Not applicable |
| Current patent term extension |
None identified |
| Current market exclusivity |
None identified |
The practical loss of exclusivity did not produce a large, durable generic market. The more important commercial event was therapeutic displacement. Hospitals migrated toward agents with faster emergence, more predictable recovery, lower metabolite concerns, or broader operating-room familiarity.
What is the FDA and Orange Book status of Ethrane?
Ethrane is not a current growth product in the FDA-approved U.S. anesthetic market. Historical FDA labeling identifies enflurane as an inhaled general anesthetic, but current U.S. product availability is limited or absent compared with the active markets for sevoflurane, isoflurane, and related products.[1][2]
The Orange Book is not a source of current commercial relevance for Ethrane. No active Orange Book patent listing is expected to support a branded or authorized-generic strategy for the legacy product. The key distinction is between historical FDA approval and current commercial supply. A product can retain an archived regulatory record while having no meaningful active U.S. sales.
| FDA and Orange Book issue |
Assessment |
| Historical FDA approval |
Yes |
| Current branded commercial position |
No material position |
| Active Orange Book patent estate |
None of commercial significance |
| Paragraph IV exposure |
Not commercially relevant |
| Abbreviated New Drug Application opportunity |
Technically possible, commercially unattractive |
| Current reference-product franchise |
Effectively obsolete |
A new manufacturer seeking to market enflurane would face the economics of a mature, low-volume anesthetic rather than the economics of a conventional generic launch. The regulatory filing cost, manufacturing controls, stability work, vaporizer compatibility, and limited customer demand would constrain returns.
How did Ethrane’s market decline?
Ethrane’s decline resulted from product substitution, operating-room preferences, safety considerations, and procurement economics.
Sevoflurane displaced enflurane in many procedures
Sevoflurane has low blood-gas solubility and permits rapid adjustment of anesthetic depth. It is also nonpungent and is widely used for inhalational induction, particularly in pediatric anesthesia. These characteristics gave sevoflurane a stronger position than enflurane in modern operating rooms.
Desflurane competed on rapid emergence
Desflurane offered very rapid changes in anesthetic concentration and recovery. Its higher acquisition cost, airway irritation, and environmental concerns later weakened its position, but it remained a more modern alternative to enflurane for many years.
Isoflurane remained a lower-cost legacy comparator
Isoflurane is more established as a low-cost volatile anesthetic and remained available in many markets. It has slower onset and recovery than sevoflurane or desflurane but is inexpensive and clinically familiar.
Propofol reduced reliance on volatile anesthetics
Propofol-based total intravenous anesthesia provided an alternative to volatile agents for selected procedures. It also became important in ambulatory surgery and settings where rapid recovery, reduced postoperative nausea, or avoidance of inhaled anesthetics was prioritized.
How does Ethrane compare with competing anesthetics?
| Product |
Active ingredient |
Relative commercial position |
Recovery profile |
Main competitive advantage |
| Ethrane |
Enflurane |
Obsolete or discontinued |
Slower than newer agents |
Historical availability |
| Forane |
Isoflurane |
Mature, low-cost |
Intermediate to slow |
Price and familiarity |
| Ultane and generic products |
Sevoflurane |
Established |
Rapid |
Low blood-gas solubility and nonpungency |
| Suprane and generic products |
Desflurane |
Established but pressured |
Very rapid |
Rapid titration and emergence |
| Diprivan and generic products |
Propofol |
Major intravenous alternative |
Rapid |
Total intravenous anesthesia |
Ethrane does not have a credible clinical or economic advantage over these alternatives. Its remaining use, where present, is likely driven by legacy equipment, local procurement, historical practice, or availability in markets with different product-registration patterns.
What was Ethrane’s financial trajectory?
Ethrane’s financial trajectory was a long-term decline from a branded hospital product to a commercially immaterial legacy anesthetic.
Abbott did not separately disclose Ethrane revenue in a way that permits a reliable product-level historical revenue series. The product was part of broader pharmaceutical or hospital-product portfolios, and public filings generally aggregated revenue across therapeutic categories and products.
The financial path can be summarized as follows:
| Period |
Financial position |
| 1970s-1980s |
Branded specialty anesthetic with hospital use |
| 1990s |
Mature product facing newer volatile agents |
| 2000s |
Declining demand and reduced strategic importance |
| 2010s |
Legacy or discontinued status in major markets |
| Current period |
No meaningful standalone commercial revenue base |
Ethrane’s economics deteriorated for four reasons:
- Unit demand declined as hospitals adopted newer anesthetics.
- The product lacked durable differentiation after patent expiry.
- Volatile anesthetics are institutional products purchased through hospital formularies and tenders.
- Low-volume manufacturing became less attractive relative to higher-demand alternatives.
The product’s financial value therefore shifted from recurring pharmaceutical revenue to potential residual value in legacy registrations, inventory, manufacturing rights, or geographic supply arrangements. No evidence indicates that Ethrane remains a material contributor to Abbott’s current revenue.
What generic-entry risks exist for Ethrane?
Generic entry risk is not the central issue because the market has already moved beyond the product.
A conventional generic manufacturer would face little patent risk but substantial commercial risk. The relevant barriers would include:
- Limited demand from hospitals and anesthesia departments
- Scarce or discontinued manufacturing capacity
- Requirements for validated volatile-liquid filling and packaging
- Compatibility with vaporizers and anesthesia delivery systems
- Supply-chain qualification by hospitals and group purchasing organizations
- Low expected volume relative to registration and manufacturing costs
- Competition from established alternatives with stronger clinical adoption
The likely generic-launch scenario would be a niche product serving a small number of markets rather than a broad U.S. launch. A manufacturer would need a low-cost supply model, existing inhaled-anesthetic infrastructure, and a customer base already using enflurane.
What patent protection remains for Ethrane?
No economically relevant patent estate remains around Ethrane.
Active ingredient patents
Enflurane’s active-ingredient protection expired decades ago. A new enflurane product would not face a modern composition-of-matter patent blocking entry.
Formulation patents
Ethrane is a simple volatile liquid rather than a complex drug-delivery system. Its commercial formulation does not have the type of layered patent protection seen in long-acting injectables, inhalers with proprietary devices, biologics, or modified-release tablets.
Potential formulation issues include purity, container compatibility, stability, vaporizer performance, and packaging. These are manufacturing and quality-control considerations, not meaningful exclusivity rights.
Method-of-use patents
No active method-of-use patent is known to create a commercial barrier around the conventional use of enflurane for general anesthesia. New clinical claims would be difficult to monetize because competing anesthetics already address the same broad procedural need.
Manufacturing and process protection
Manufacturing know-how may still have operational value, particularly for purification, impurity control, packaging, and vaporizer delivery. It would not create a defensible high-margin franchise unless protected by trade secrets and supported by a stable customer base.
Which companies challenge or replace Ethrane?
No significant current Paragraph IV campaign targets Ethrane. The relevant competitive activity occurred through substitution rather than patent litigation.
The competitive landscape includes:
- Abbott, historically associated with Ethrane
- Baxter and other hospital-product suppliers, historically active in inhaled anesthetics
- Piramal Critical Care and other manufacturers supplying sevoflurane, isoflurane, or desflurane
- Generic manufacturers of volatile anesthetics
- Fresenius Kabi and other suppliers competing in intravenous anesthesia, including propofol
- Regional pharmaceutical companies supplying legacy anesthetics in selected markets
The companies with the strongest current position are those with active manufacturing, regulatory registrations, hospital contracts, and reliable supply of sevoflurane, isoflurane, desflurane, or propofol.
What litigation and settlement agreements affect Ethrane?
No material current patent litigation or settlement agreement appears to affect Ethrane’s commercial position.
Historical disputes, if any, would be unlikely to affect current market entry because the relevant patent terms have expired and the brand is no longer a meaningful commercial reference product. The absence of active litigation is itself consistent with the product’s low commercial value.
| Legal issue |
Current assessment |
| Active patent litigation |
No material case identified |
| Paragraph IV settlements |
None of current commercial significance |
| Patent-term disputes |
No current relevance |
| Antitrust exposure |
Low relative to active blockbuster products |
| Trade-secret exposure |
Possible at manufacturing level, but not publicly established |
| Product-liability exposure |
Legacy risk may exist, but not a market-growth factor |
What is the geographic coverage of Ethrane?
Ethrane’s commercial availability varies by jurisdiction. Historical registration does not establish current supply. Some legacy anesthetics remain available in emerging markets or specialized hospital channels after withdrawal from the United States and Western Europe.
Geographic commercial value is limited by:
- Local registration status
- National hospital tenders
- Availability of compatible vaporizers
- Local anesthesia practice
- Import controls for pharmaceutical gases and volatile agents
- Regional manufacturing capacity
- Procurement preference for sevoflurane or isoflurane
A regional relaunch could be technically possible where enflurane remains registered or clinically familiar. It would not create a global franchise without substantial new clinical, regulatory, and supply investment.
What manufacturing and IP barriers remain?
The principal barriers are operational rather than patent-based.
A manufacturer would need:
- Pharmaceutical-grade enflurane production or a qualified active-ingredient supplier.
- Control of residual impurities and degradation products.
- Compatible containers and closures for a volatile halogenated liquid.
- Stability data under required storage conditions.
- Validated filling and packaging operations.
- Vaporizer performance data.
- Regulatory submissions in each target jurisdiction.
- Hospital procurement and pharmacovigilance infrastructure.
These requirements could deter entry despite the absence of patent protection. They do not support premium pricing because hospitals can substitute other volatile anesthetics.
What is the investment outlook for Ethrane?
Ethrane has no credible standalone investment thesis as an active pharmaceutical product. Its commercial profile is characterized by:
| Investment factor |
Assessment |
| Revenue growth |
None expected |
| Patent runway |
None |
| Pricing power |
Minimal |
| Competitive differentiation |
Weak |
| Manufacturing scarcity |
Potentially relevant but not durable |
| Regulatory upside |
Limited |
| Litigation risk |
Low |
| Generic threat |
High in theory, but market demand is too low |
| Acquisition value |
Limited to residual assets or geographic rights |
| Strategic value |
Possible only within a broader anesthetic portfolio |
Any value would likely reside in a portfolio transaction involving manufacturing assets, hospital contracts, or regional registrations rather than in Ethrane itself.
Key Takeaways
- Ethrane is the former Abbott brand for enflurane, a legacy volatile general anesthetic.
- Its patent and regulatory exclusivity expired decades ago.
- No meaningful active patent estate, Orange Book listing, or Paragraph IV dispute supports the product.
- Ethrane was displaced by sevoflurane, desflurane, isoflurane, and propofol.
- Abbott did not report a standalone Ethrane revenue stream that supports a reliable financial model.
- Current commercial value is negligible in major pharmaceutical markets.
- Any residual opportunity would be regional and supply-driven, not patent-driven.
- Manufacturing, registration, and hospital procurement are the main barriers to re-entry.
- The most likely market outcome is continued decline, with no material branded recovery.
FAQs About Ethrane Market Value and Exclusivity
Is Ethrane still sold in the United States?
Ethrane is not a meaningful current commercial product in the U.S. anesthetic market. Historical FDA approval and labeling do not establish present commercial availability.
Who manufactured Ethrane?
Abbott Laboratories was the original major manufacturer and brand owner associated with Ethrane. Current regional availability, where it exists, may involve other suppliers or legacy registrations.
Is enflurane generic?
Enflurane is an off-patent active ingredient. Any current product would be a generic or legacy product rather than a protected branded innovation.
Could a pharmaceutical company relaunch Ethrane?
A relaunch could be technically possible in selected jurisdictions, but the commercial case is weak because competing anesthetics have stronger adoption, established supply chains, and more favorable clinical profiles.
Does Ethrane have biosimilar competition?
No. Biosimilar regulation applies to biological products. Ethrane is a small-molecule volatile anesthetic, so any competition would involve generic or therapeutically substitutable products.
References
-
U.S. Food and Drug Administration. (n.d.). Ethrane (enflurane) inhalation anesthetic: Prescribing information. FDA archival labeling.
-
U.S. National Library of Medicine. (n.d.). Enflurane. DailyMed.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
Eger, E. I., II. (2001). The pharmacology of inhaled anesthetics. Seminars in Anesthesia, Perioperative Medicine and Pain, 20(1), 1-10.
-
World Health Organization. (2021). WHO model list of essential medicines: 22nd list. World Health Organization.
